Minimal uterine serous carcinoma: current concepts in diagnosis and prognosis

References

• Cullen T. S. Cancer of the Uterus: Its Pathology, Symptomatology, Diagnosis, and Treatment. D Appleton and Company, New York 1900
   Google Scholar
• Lax S. F. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular‐based classification. Virchows Arch 2004; 444: 213–23
   PubMed Web of Science ®Google Scholar
• Bokhman J. V. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10–7
   PubMed Web of Science ®Google Scholar
• Silverberg S. G., Kurman R. J., Nogales F., Mutter G. L., Kubick‐Huch R. A., Tavassoli F. A. Tumors of the Uterine Corpus. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs, F. A Tavassoli, P Devilee. IARC Press, Lyon 2003
   Google Scholar
• Ambros R. A., Sherman M. E., Zahn C. M., Bitterman P., Kurman R. J. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995; 26: 1260–7
   PubMed Web of Science ®Google Scholar
• Sherman M. E., Bitterman P., Rosenshein N. B., Delgado G., Kurman R. J. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992; 16: 600–10
   PubMed Web of Science ®Google Scholar
• Spiegel G. W. Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol 1995; 19: 417–32
   PubMed Web of Science ®Google Scholar
• Hui P., Kelly M., O'Malley D. M., Tavassoli F., Schwartz P. E. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Mod Pathol 2005; 18: 75–82
   PubMed Web of Science ®Google Scholar
• Wheeler D. T., Bell K. A., Kurman R. J., Sherman M. E. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol 2000; 24: 797–806
   PubMed Web of Science ®Google Scholar
• Carcangiu M. L., Tan L. K., Chambers J. T. Stage IA uterine serous carcinoma: a study of 13 cases. Am J Surg Pathol 1997; 21: 1507–14
   PubMed Web of Science ®Google Scholar
• Soslow R. A., Pirog E., Isacson C. Endometrial intraepithelial carcinoma with associated peritoneal carcinomatosis. Am J Surg Pathol 2000; 24: 726–32
   PubMed Web of Science ®Google Scholar
• Zheng W., Khurana R., Farahmand S., Wang Y., Zhang Z. F., Felix J. C. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am J Surg Pathol 1998; 22: 1463–73
   PubMed Web of Science ®Google Scholar
• Silverberg S. G., Kurman R. J., Nogales F., Mutter G. L., Kubick‐Huch R. A., Tavassoli F. A. Tumors of the Uterus. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Breast and Female Genital Organs, F. A Tavassoli, P Devilee. IARC Press, Lyon 2003; 225
   Google Scholar
• Tashiro H., Isacson C., Levine R., Kurman R. J., Cho K. R., Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997; 150: 177–85
   PubMed Web of Science ®Google Scholar
• Carcangiu M. L., Chambers J. T. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 1992; 47: 298–305
   PubMed Web of Science ®Google Scholar
• Baergen R. N., Warren C. D., Isacson C., Ellenson L. H. Early uterine serous carcinoma: clonal origin of extrauterine disease. Int J Gynecol Pathol 2001; 20: 214–9
   PubMed Web of Science ®Google Scholar
• Dietrich C. S., III., Modesitt S. C., DePriest P. D., et al. The efficacy of adjuvant platinum‐based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Gynecol Oncol 2005; 99: 557–63
   PubMed Web of Science ®Google Scholar
• Kelly M. G., O'Malley D. M., Hui P., et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum‐based chemotherapy. Gynecol Oncol 2005; 98: 353–9
   PubMed Web of Science ®Google Scholar
• Acs G., Pasha T., Zhang P. J. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 2004; 23: 110–8
   PubMed Web of Science ®Google Scholar
• McCluggage W. G. WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int J Gynecol Pathol 2004; 23: 97–9
   PubMed Web of Science ®Google Scholar
• Shimizu M., Toki T., Takagi Y., Konishi I., Fujii S. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 2000; 19: 158–63
   PubMed Web of Science ®Google Scholar
• Al‐Hussaini M., Stockman A., Foster H., McCluggage W. G. WT‐1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 2004; 44: 109–15
   PubMed Web of Science ®Google Scholar
• Egan J. A., Ionescu M. C., Eapen E., Jones J. G., Marshall D. S. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int J Gynecol Pathol 2004; 23: 119–22
   PubMed Web of Science ®Google Scholar
• Schedl A., Hastie N. Multiple roles for the Wilms' tumour suppressor gene, WT1 in genitourinary development. Mol Cell Endocrinol 1998; 140: 65–9
   PubMed Web of Science ®Google Scholar
• Gray C. A., Bartol F. F., Tarleton B. J., et al. Developmental biology of uterine glands. Biol Reprod 2001; 65: 1311–23
   PubMed Web of Science ®Google Scholar
• Euscher E. D., Malpica A., Deavers M. T., Silva E. G. Differential expression of WT‐1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps. Am J Surg Pathol 2005; 29: 1074–8
   PubMed Web of Science ®Google Scholar
• Kupryjanczyk J., Thor A. D., Beauchamp R., Poremba C., Scully R. E., Yandell D. W. Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease. Mod Pathol 1996; 9: 166–73
   PubMed Web of Science ®Google Scholar
• Demopoulos R. I., Mesia A. F., Mittal K., Vamvakas E. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis. Int J Gynecol Pathol 1999; 18: 233–7
   PubMed Web of Science ®Google Scholar
• Lax S. F., Pizer E. S., Ronnett B. M., Kurman R. J. Comparison of estrogen and progesterone receptor, Ki‐67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation. Hum Pathol 1998; 29: 924–31
   PubMed Web of Science ®Google Scholar
• Zheng W., Cao P., Zheng M., Kramer E. E., Godwin T. A. p53 overexpression and bcl‐2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 1996; 61: 167–74
   PubMed Web of Science ®Google Scholar
• Lax S. F., Pizer E. S., Ronnett B. M., Kurman R. J. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki‐67, estrogen, and progesterone receptor expression. Hum Pathol 1998; 29: 551–8
   PubMed Web of Science ®Google Scholar
• Hendrickson M. R., Kempson R. L. Endometrial epithelial metaplasias: proliferations frequently misdiagnosed as adenocarcinoma. Report of 89 cases and proposed classification. Am J Surg Pathol 1980; 4: 525–542
   PubMed Web of Science ®Google Scholar
• Quddus M. R., Sung C. J., Zheng W., Lauchlan S. C. p53 immunoreactivity in endometrial metaplasia with dysfunctional uterine bleeding. Histopathology 1999; 35: 44–9
   PubMed Web of Science ®Google Scholar
• Arias‐Stella J. The Arias‐Stella reaction: facts and fancies four decades after. Adv Anat Pathol 2002; 9: 12–23
   PubMed Web of Science ®Google Scholar
• Vang R., Barner R., Wheeler D. T., Strauss B. L. Immunohistochemical staining for Ki‐67 and p53 helps distinguish endometrial Arias‐Stella reaction from high‐grade carcinoma, including clear cell carcinoma. Int J Gynecol Pathol 2004; 23: 223–33
   PubMed Web of Science ®Google Scholar
• Reid‐Nicholson M., Iyengar P., Hummer A. J., Linkov I., Asher M., Soslow R. A. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 2006; 19: 1091–100
   PubMed Web of Science ®Google Scholar
• Cina S. J., Richardson M. S., Austin R. M., Kurman R. J. Immunohistochemical staining for Ki‐67 antigen, carcinoembryonic antigen, and p53 in the differential diagnosis of glandular lesions of the cervix. Mod Pathol 1997; 10: 176–80
   PubMed Web of Science ®Google Scholar
• McCluggage G., McBride H., Maxwell P., Bharucha H. Immunohistochemical detection of p53 and bcl‐2 proteins in neoplastic and non‐neoplastic endocervical glandular lesions. Int J Gynecol Pathol 1997; 16: 22–7
   PubMed Web of Science ®Google Scholar
• Leary J., Jaworski R., Houghton R. In‐situ hybridization using biotinylated DNA probes to human papillomavirus in adenocarcinoma‐in‐situ and endocervical glandular dysplasia of the uterine cervix. Pathology 1991; 23: 85–9
   PubMed Web of Science ®Google Scholar
• Tase T., Okagaki T., Clark B. A., Twiggs L. B., Ostrow R. S., Faras A. J. Human papillomavirus DNA in adenocarcinoma in situ, microinvasive adenocarcinoma of the uterine cervix, and coexisting cervical squamous intraepithelial neoplasia. Int J Gynecol Pathol 1989; 8: 8–17
   PubMed Web of Science ®Google Scholar
• Baker P. M., Clement P. B., Bell D. A., Young R. H. Superficial endometriosis of the uterine cervix: a report of 20 cases of a process that may be confused with endocervical glandular dysplasia or adenocarcinoma in situ. Int J Gynecol Pathol 1999; 18: 198–205
   PubMed Web of Science ®Google Scholar
• Nezhat F., Cohen C., Rahaman J., Gretz H., Cole P., Kalir T. Comparative immunohistochemical studies of bcl‐2 and p53 proteins in benign and malignant ovarian endometriotic cysts. Cancer 2002; 94: 2935–40
   PubMed Web of Science ®Google Scholar
• Nezhat F. R., Kalir T. Comparative immunohistochemical studies of endometriosis lesions and endometriotic cysts. Fertil Steril 2002; 78: 820–4
   PubMed Web of Science ®Google Scholar
• Schneider J., Jimenez E., Rodriguez F., del Tanago J. G. c‐myc, c‐erb‐B2, nm23 and p53 expression in human endometriosis. Oncol Rep 1998; 5: 49–52
   PubMed Web of Science ®Google Scholar
• Oliva E., Clement P. B., Young R. H. Tubal and tubo‐endometrioid metaplasia of the uterine cervix. Unemphasized features that may cause problems in differential diagnosis: a report of 25 cases. Am J Clin Pathol 1995; 103: 618–23
   PubMed Web of Science ®Google Scholar
• Suh K. S., Silverberg S. G. Tubal metaplasia of the uterine cervix. Int J Gynecol Pathol 1990; 9: 122–8
   PubMed Web of Science ®Google Scholar
• Nucci M. R., Young R. H. Arias‐Stella reaction of the endocervix: a report of 18 cases with emphasis on its varied histology and differential diagnosis. Am J Surg Pathol 2004; 28: 608–12
   PubMed Web of Science ®Google Scholar
• McCluggage W. G., Sumathi V. P., McManus D. T. Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endometrial polyps: report of 5 cases, including 2 associated with tamoxifen therapy. Hum Pathol 2003; 34: 939–43
   PubMed Web of Science ®Google Scholar
• Alkushi A., Lim P., Coldman A., Huntsman D., Miller D., Gilks C. B. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut‐off level. Int J Gynecol Pathol 2004; 23: 129–37
   PubMed Web of Science ®Google Scholar